SCN2A and epilepsy: ,10, 11, 12, 13, 14 Through functional studies, we can delineate their distinct disease mechanisms and more clearly define the mechanisms of variants causing predominantly ataxia, contributing towards both a timely and accurate diagnosis as well as precision medicine approaches for individuals affected by these variants: In SCN2A- and SCN8A-associated epilepsy, treatment with sodium channel blockers (SCBs) has been shown to be beneficial in GOF-variant carriers, but unfavourable in those carrying LOF variants.8